Foundations Investment Advisors LLC Grows Position in GSK plc (NYSE:GSK)

Foundations Investment Advisors LLC increased its position in GSK plc (NYSE:GSK) by 4.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,122 shares of the pharmaceutical company’s stock after purchasing an additional 466 shares during the period. Foundations Investment Advisors LLC’s holdings in GSK were worth $414,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in GSK. Ledyard National Bank grew its holdings in GSK by 24.1% in the third quarter. Ledyard National Bank now owns 24,281 shares of the pharmaceutical company’s stock worth $993,000 after purchasing an additional 4,712 shares during the period. Allspring Global Investments Holdings LLC increased its position in GSK by 40.7% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 11,764 shares of the pharmaceutical company’s stock valued at $481,000 after buying an additional 3,405 shares in the last quarter. Blue Trust Inc. raised its stake in GSK by 335.1% during the third quarter. Blue Trust Inc. now owns 10,720 shares of the pharmaceutical company’s stock valued at $413,000 after buying an additional 8,256 shares during the last quarter. Aaron Wealth Advisors LLC boosted its holdings in GSK by 11.3% in the third quarter. Aaron Wealth Advisors LLC now owns 20,711 shares of the pharmaceutical company’s stock worth $847,000 after acquiring an additional 2,103 shares in the last quarter. Finally, Cardinal Capital Management grew its stake in shares of GSK by 1.5% in the third quarter. Cardinal Capital Management now owns 56,372 shares of the pharmaceutical company’s stock worth $2,326,000 after acquiring an additional 808 shares during the last quarter. Institutional investors own 15.74% of the company’s stock.

Insider Transactions at GSK

In other GSK news, major shareholder Plc Gsk bought 2,791,930 shares of GSK stock in a transaction on Friday, September 27th. The stock was acquired at an average cost of $8.00 per share, with a total value of $22,335,440.00. Following the completion of the acquisition, the insider now owns 16,775,691 shares in the company, valued at approximately $134,205,528. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 10.00% of the company’s stock.

GSK Stock Down 0.6 %

Shares of GSK stock opened at $37.51 on Friday. The company has a quick ratio of 0.54, a current ratio of 0.82 and a debt-to-equity ratio of 0.99. GSK plc has a twelve month low of $33.67 and a twelve month high of $45.92. The company has a market cap of $77.74 billion, a price-to-earnings ratio of 13.59, a price-to-earnings-growth ratio of 1.30 and a beta of 0.65. The company’s 50 day moving average is $41.20 and its 200 day moving average is $41.16.

GSK (NYSE:GSK) last released its quarterly earnings results on Wednesday, July 31st. The pharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.00 by $0.09. The firm had revenue of $9.95 billion for the quarter, compared to the consensus estimate of $9.49 billion. GSK had a return on equity of 51.48% and a net margin of 12.87%. Research analysts anticipate that GSK plc will post 4.14 EPS for the current year.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, October 10th. Stockholders of record on Friday, August 16th were given a dividend of $0.3843 per share. The ex-dividend date of this dividend was Friday, August 16th. This represents a $1.54 annualized dividend and a dividend yield of 4.10%. This is a positive change from GSK’s previous quarterly dividend of $0.38. GSK’s dividend payout ratio is presently 55.80%.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. UBS Group cut shares of GSK from a “buy” rating to a “neutral” rating in a research note on Monday, July 8th. Jefferies Financial Group increased their price target on shares of GSK from $52.50 to $53.00 and gave the company a “buy” rating in a report on Tuesday, July 2nd. Barclays upgraded shares of GSK to a “hold” rating in a report on Tuesday, August 27th. Finally, Argus upgraded GSK to a “strong-buy” rating in a research note on Wednesday, August 7th. Four equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and four have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, GSK presently has an average rating of “Buy” and an average price target of $50.00.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.